Abel Stephen, Renz Paul, Gayou Olivier, Tang Jie, Werts E Day, Trombetta Mark
Lake Erie College of Osteopathic Medicine, Bradenton, FL.
Division of Radiation Oncology, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA.
J Contemp Brachytherapy. 2017 Aug;9(4):309-315. doi: 10.5114/jcb.2017.69412. Epub 2017 Aug 1.
Intraoperative planning with transrectal ultrasound (US) is used for accurate seed placement and optimal dosimetry in prostate brachytherapy. However, prostate magnetic resonance imaging (MRI) has shown superiority in delineation of prostate anatomy. Accordingly, MRI/US fusion may be useful for accurate intraoperative planning. We analyzed planning with MRI/US fusion to compare differences in dosimetry and volume to that derived from the postoperative computed tomography (CT).
Twenty patients underwent preoperative prostate MRI, which was fused intraoperatively with US during prostate brachytherapy. Intraoperative I or Pd seed placement was modified by the use of MRI fusion when indicated. Following implantation, dose comparisons were made between data derived from MRI/US and that from post-operative CT scans. Plan parameters analyzed included the D (dose to 90% of the prostate), rectal D, V (volume of the rectum receiving 30 percent of dose), and prostate V.
The median number of seeds implanted per patient was seventy-six. The MRI measured prostate volume, which was on average 4.47 cc larger than the CT measured prostate volume. In 9 patients, the apex of the prostate was better identified under MRI with the fusion protocol, and an average of 4 fewer seeds were required to be placed in the apex/urinary sphincter region. Both MRI and US individually showed a reduced intraoperative prostate D in comparison to the postoperative CT, with a larger mean difference for MRI in comparison with US (9.71 vs. 4.31 Gy, = 0.007). This was also true for the prostate V (5.18 vs. 2.73 cc, = 0.009). Post-operative CT underestimated rectal D and V in comparison to both MRI and US with MRI showing a larger mean difference than US for D (40.64 vs. 35.92 Gy, = 0.04) and V (50.20 vs. 44.38 cc, = 0.009).
The MRI/US fusion demonstrated greater prostate volume compared to standard CT/US based planning likely due to the better resolution of the prostate apex. Furthermore, rectal dose was underestimated with CT vs. MRI based planning. Additional study is required to assess long-term clinical implications of disease control and effects on long-term toxicity, especially as related to the rectum and urinary sphincter. MRI/US intraoperative fusion may improve prostate dosimetry while sparing the rectum and urethra, potentially impacting disease control and late toxicity.
在前列腺近距离放射治疗中,经直肠超声(US)引导的术中规划用于精确植入粒子及优化剂量测定。然而,前列腺磁共振成像(MRI)在前列腺解剖结构的描绘方面显示出优势。因此,MRI/US融合可能有助于精确的术中规划。我们分析了MRI/US融合规划,以比较剂量测定和体积与术后计算机断层扫描(CT)结果的差异。
20例患者在前列腺近距离放射治疗术前接受了前列腺MRI检查,并在术中与US进行融合。必要时,利用MRI融合技术调整术中碘-125或钯-103粒子的植入位置。植入后,对MRI/US数据与术后CT扫描数据进行剂量比较。分析的计划参数包括前列腺D90(前列腺90%体积所接受的剂量)、直肠D、V30(接受30%剂量的直肠体积)和前列腺体积。
每位患者植入粒子的中位数为76粒。MRI测量的前列腺体积平均比CT测量的前列腺体积大4.47立方厘米。9例患者中,在MRI融合方案下,前列腺尖部的识别更佳,且在尖部/尿道括约肌区域平均少植入4粒粒子。与术后CT相比,MRI和US单独测量均显示术中前列腺D降低,其中MRI的平均差异大于US(9.71对4.31 Gy,P = 0.007)。前列腺体积情况也是如此(5.18对2.73立方厘米,P = 0.009)。与MRI和US相比,术后CT低估了直肠D和V,其中MRI显示的D平均差异大于US(40.64对35.92 Gy,P = 0.04),V的平均差异也大于US(50.20对44.38立方厘米,P = 0.009)。
与基于标准CT/US的规划相比,MRI/US融合显示出更大的前列腺体积,这可能是由于前列腺尖部的分辨率更高。此外,基于CT的规划与基于MRI的规划相比,直肠剂量被低估。需要进一步研究以评估疾病控制的长期临床意义以及对长期毒性的影响,特别是与直肠和尿道括约肌相关的影响。MRI/US术中融合可能改善前列腺剂量测定,同时保护直肠和尿道,这可能会影响疾病控制和晚期毒性。